Q-omics provides the consensus-scored RANBP17 profile across patient tissues and cancer cell-line models. RANBP17 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RANBP17 is differentially expressed in 14, with the highest sampling consensus in STAD. Additionally, RANBP17 RNA expression shows 18,891 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight HNSC, STAD, and UVM as cancer lineages where RANBP17 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RANBP17 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RANBP17 survival associations across molecular data types. RANBP17 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (10) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RANBP17 RNA expression–survival associations across cancer types. High RANBP17 expression shows unfavorable associations in UVM, STAD and KIRP, but favorable associations in HNSC, READ and LGG. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .003). Together, the overview and detailed table identify HNSC as the clearest survival context for RANBP17 RNA expression.
This table summarizes RANBP17 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 2. The strongest signals are observed in STAD for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RANBP17. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RANBP17 shows lower tumor expression in THCA and higher tumor expression in STAD, COAD, UCEC, READ and BLCA. The STAD box plot shows higher RANBP17 RNA expression in tumor versus normal tissue (log2 FC = +0.497, t-test p < 0.001).
This table shows molecular features associated with RANBP17 in patient tissues and cancer cell lines. In patient samples, RANBP17 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RANBP17 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
